INVESTOR NOTICE: Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus AI's joint venture with SoftBank Group Corporation, suggesting it created an appearance of "round-tripping" capital to inflate revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is alleged to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca PLC reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, raising further concerns about the company's financial health [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report from Spruce Point Capital Management raised multiple red flags regarding Tempus AI's management, operations, and financial reporting, resulting in a stock price drop of over 19% [4]. Group 3: Class Action Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Tempus AI common stock during the specified Class Period to seek appointment as lead plaintiff in the class action lawsuit [5]. - A lead plaintiff is typically the investor with the greatest financial interest in the case and acts on behalf of all other class members [5]. - Investors can choose their own law firm to represent them in the lawsuit, and participation as lead plaintiff does not affect their ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years, indicating its strong track record in obtaining monetary relief for investors [6].